Syros Pharmaceuticals’ (SYRS) Hold Rating Reiterated at TD Cowen

Syros Pharmaceuticals (NASDAQ:SYRS)‘s stock had its “hold” rating reaffirmed by analysts at TD Cowen in a research note issued to investors on Wednesday, Marketbeat.com reports.

A number of other equities research analysts have also weighed in on the stock. StockNews.com lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Syros Pharmaceuticals in a report on Friday, November 1st. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, JMP Securities cut their price objective on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Syros Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Trading Down 23.4 %

NASDAQ SYRS opened at $0.28 on Wednesday. The stock has a market cap of $7.38 million, a P/E ratio of -0.11 and a beta of 1.59. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a 12 month low of $0.27 and a 12 month high of $8.17. The stock’s fifty day moving average price is $2.04 and its 200-day moving average price is $3.81.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm posted ($1.35) earnings per share. As a group, equities analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Activity at Syros Pharmaceuticals

In related news, CEO Conley Chee bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. The trade was a 222.18 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jason Haas purchased 45,344 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the purchase, the chief financial officer now owns 124,552 shares in the company, valued at approximately $209,247.36. This represents a 57.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 130,707 shares of company stock worth $206,491. 12.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SYRS. Kennedy Capital Management LLC purchased a new stake in shares of Syros Pharmaceuticals in the first quarter worth about $2,166,000. Vanguard Group Inc. raised its holdings in shares of Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Syros Pharmaceuticals during the 1st quarter valued at approximately $64,000. Acadian Asset Management LLC purchased a new position in shares of Syros Pharmaceuticals in the first quarter valued at $91,000. Finally, Certuity LLC bought a new stake in Syros Pharmaceuticals in the second quarter worth $109,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.